Guangji Pharmaceutical announced that it plans to issue up to 94.94 million A-shares to its controlling shareholder, Changjiang Industry Investment Group, raising total proceeds of up to 600 million yuan. Changjiang Industry Investment Group will subscribe to all shares in cash. The raised funds will be used to repay borrowings and replenish working capital. As of March 31, 2026, the company's asset-liability ratio was 74.12 percent. This private placement aims to reduce reliance on debt financing and optimize the capital structure. In the first quarter of 2026, the company achieved revenue of 163 million yuan, with a net loss attributable to the parent company of 31.64 million yuan.
Hubei Guangji Pharmaceutical Co LtdControlling shareholder fully subscribes to 600M yuan private placement to repay debt and improve capital structure.